Amgen Faces Lawsuit For Hiding Its Stupendous Tax Bill Of $10B
In a complaint filed in Manhattan federal court, a Detroit-based pension fund said Amgen Inc (NASDAQ:AMGN) concealed the dispute over…
Analyst Says Biogen-Eisai’s Alzheimer’s Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Eisai Co Ltd (OTC:ESALY) and Biogen Inc (NASDAQ:BIIB) said the U.S. Department of Veteran Affairs (VA) would provide coverage of their…
Puma Biotechnology Announces Publication Of Phase II Clinical Trial Of Alisertib In JAMA Oncology
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with
Synaffix Has Announced The Expansion Of Its License Agreement With Macrogenics Adding Up To Four Antibody-drug Conjugates Programs; Expanded Collaboration Includes Up To $2.2B In Total Potential Payments
The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion, plus tiered low to high single-digit royalties on potential net
Atea Pharmaceuticals Announced The Presentation Of New Phase 1, In Vitro And In Vivo Data That Demonstrate Key Profile Attributes Of Atea’s Lead Drug Candidate, Bemnifosbuvir, For Covid-19 And Hepatitis C
Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies
Bemnifosbuvir retains activity against all SARS-CoV-2 variants of concern evaluated as well as
Enanta Pharmaceuticals To Present New Data For EDP-235 In Development As An Oral, Once-daily Treatment For Covid-19, At The International Conference On Antiviral Research
Phase 1 Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Supportive of Once-Daily Dosing Without Ritonavir
Preclinical Animal Data Indicate the Potential for EDP-235 to Reduce Household
Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?
Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr.
Reported Late Monday March 13, Everest Medicines Announces Partner Calliditas Therapeutics Reports Topline Results From Phase 3 NefIgArd Trial Evaluating Nefecon In IgA Nephropathy; Trial Primary Endpoint Was Met With Nefecon
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX)))) ("Calliditas") reported
Reported Late Monday March 13, Reunion Neuroscience Files Lawsuit Against Mindset Pharma Alleging That Mindset Knowingly Copied Reunion’s RE104 Compound And Misleadingly Presented That Exact Composition To The Patent Office As Mindset’s Invention
Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion"